Mucociliary and cough clearance as a biomarker for therapeutic development

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 5, 2010, Pages 261-272

  Bennett, William D ^a   Daviskas, Evangelia ^b   Hasani, Amir ^c   Mortensen, Jann ^d   Fleming, John ^e   Scheuch, Gerhard ^f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^f Activaero GmbH   (Germany)

Author keywords

aerosol deposition; cough clearance; mucociliary clearance; particle clearance

Indexed keywords

BIOLOGICAL MARKER; MANNITOL; PLACEBO; SODIUM CHLORIDE; TECHNETIUM 99M; XENON 133;

COUGHING; CYSTIC FIBROSIS; HUMAN; IN VIVO STUDY; INHALATION; ISOTOPE LABELING; LUNG CLEARANCE; MUCOCILIARY CLEARANCE; PARTICLE SIZE; RESPIRATORY TRACT DISEASE; REVIEW; WORKSHOP;

ANIMALS; BIOLOGICAL MARKERS; COUGH; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; MUCOCILIARY CLEARANCE; RESPIRATORY TRACT DISEASES;

EID: 77958148495     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0823     Document Type: Review

References (62)

1. Mayer-Hamblett N, Ramsey BW, and Kronmal RA: Ad¬vancing outcome measures for the new era of drug devel¬opment in cystic fibrosis. Proc Am Thorac Soc. 2007;4: 370-377.
2. WannerA,Salathe M, O'Riordan TG: Mucociliary clearance in the airways. Am J Respir Crit Care Med. 1996;154:1868-1902.
3. Bennett WD, Almond MA, Zeman KL, Johnson JG, and Donohue JF: Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharm Ther. 2006; 19:96-100.
4. Daviskas E, Anderson SD, Eberl S, and Young IH: Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J. 2008;31:765-772.
5. Marthin JK, Mortensen J, Pressler T, and Nielsen KG: Pul¬monary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest. 2007;132:966-976.
6. Mortensen J, Lange L, Nyboe J, and Groth S: Lung muco-ciliary clearance. Eur J Nucl Med. 1994;21:953-961.
7. Lay JC, Berry CR, Kim CS, and Bennett WD: Retention of insoluble particles following local intrabronchial deposition in dogs. J Appl Physiol. 1995;79:1921-1929.
8. Chapman TH, McCool D, Smith RE, Dilworth JP, and Ag-new JE: Domiciliary humidification improves lung muco-ciliary clearance in patients with bronchiectasis. Chronic Respir Dis. 2008;5:81-86.
9. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, and Dilworth JP: The effect of inhaled Tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest. 2004;125:1726-1734.
10. Scheuch G, Stahlhofen W, and Heyder J: An approach to deposition and clearance measurements in human airways. J Aerosol Med. 1996;9:35-41.
11. Scheuch G, Kohlhäufl M, Möller W, Brand P, Meyer T, Häussinger K, Sommerer K, and Heyder J: Particle clearance from the airways of subjects with bronchial hyperrespon-siveness and with chronic obstructive pulmonary disease. Exp Lung Res. 2008;34:531-549.
12. Stahlhofen W, Gebhart J, and Heyder J: Experimental de¬termination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980;41:385-398.
13. Pavia D and Thomson ML: The fractional deposition of in¬haled 2 and 5mm particles in the alveolar and tracheobron-chial regions of the healthy human lung. Ann Occup Hyg. 1976;19:109-114.
14. Mortensen J, Falk M, Groth S, and Jensen C: The effects of postural drainage and positive expiratory pressure physio¬therapy on tracheobronchial clearance in cystic fibrosis. Chest. 1991;100:1350-1357.
15. Daviskas E, Anderson SD, Gonda I, Chan H-K, Cook P, and Fulton R: Changes in mucociliary clearance during and after isocapnic hyperventilation in asthmatic and healthy subjects. Eur Respir J 1995;8:742-751.
16. Daviskas E, Anderson SD, Eberl S, Chan H-K, and Bautovich G: Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999;159:1843-1848.
17. Phipps PR, Gonda I, and Anderson SD: Apparatus for the control of breathing during aerosol inhalation. J Aerosol Med. 1992;5:155-170.
18. Hasani A, Rotondetto S, Pavia D, Agnew JE, Clarke SW, and Spiteri MA: Effects of oral antibiotics on lung mucociliary clearance during exacerbation of chronic obstructive pul¬monary disease. Respir Med. 1998;92:442-447.
19. Hasani A, Toms N, O'Connor J, Dilworth JP, and Agnew JE: Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma. Respir Med. 2003;97: 667-671.
20. Bailey DL, Fulton RR, Jacson CB, and Hutton BF: Dynamic geometric mean studies using a single head rotating camera. J Nucl Med. 1989;30:1865-1869.
21. Regnis JA, Robinson M, Bailey DL, Cook P, Hooper P, Chan H-K, Gonda I, Bautovich G, and Bye PTP: Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med. 1994;150:66-71.
22. Robinson M, Daviskas E, Eberl E, Baker J, Chan H-K, An¬derson SD, and Bye PTP: The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J. 1999;14:678-685.
23. Hasani A, Pavia D, Spiteri MA, Yeo CT, Agnew JE, Clarke SW, and Chung KF: Inhaled frusemide does not affect lung mucociliary clearance in healthy and asthmatic subjects. Eur Respir J 1994;7:1497-1500.
24. Hasani A, Pavia D, Agnew JE, and Clarke SW: The effect of unproductive coughing/FET on regional mucus movement in the human lungs. Respir Med. 1991;85:23-26.
25. Bennett, WD, Chapman, WF, and JM Mascarella: The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest. 1993;103:488-495.
26. Eberl S, Chan H-K, Daviskas E, Constable C, and Young IH: Aerosol deposition and clearance measurement: a novel technique using dynamic SPECT. Eur J Nuclear Med. 2001;28:1365-1372.
27. Elkins M, Daviskas E, Eberl S, Constable C, and Bye P: Quantification of mucocliary clearance: 3-D SPECT versus Planar. J Aerosol Med. 2002;15:446.
28. Lee Z, and Berridge MS: PET imaging based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies IEEE Trans Med Imag. 2002;21:1324-1331.
29. Bennett WD, and Ilowite J: Dual pathway clearance of Tc99m-DTPA from the bronchial mucosa. Am Rev Respir Dis. 1989;139:1132-1138.
30. Anderson M, Philipson K, Svartengren M, and Camner P: Human deposition and clearance of 6-mm particles inhaled with an extremely low flow rate. Exp. Lung Res. 1995; 21:187-195.
31. Svartengren M, Sommerer K, Scheuch G, Kohlhaeufl M, Heyder J, Falk R, Bergmann R, Hofmann W, Bailey M, Philipson K, and Camner P: Comparison of clearance of particles inhaled with bolus and extremely slow inhalation techniques. Exp Lung Res. 2001;27:367-386.
32. Möller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, Häussinger K, and Kreyling WG: Deposition, re¬tention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med. 2008;177:426-432.
33. Smith JR, Bailey MR, Etherington G, Shutt AL, and Youngman MJ: Effect of particle size on slow particle clearance from the bronchial tree. Exp Lung Res. 2008;34: 287-312.
34. Alexis NE, Hu SC, Zeman K, Alter T, and Bennett WD: In¬duced sputum derives from the central airways: confirma¬tion using a radiolabeled aerosol bolus delivery technique. Am J Resp Crit Care Med. 2001;164:1964-1970.
35. Roth C, Scheuch G, and Stahlhofen W: Clearance of the human lung for ultrafine particles. J Aerosol Sci. 1993; 24(Suppl 1):S95-S96.
36. Lay JC, Stang MR, Fisher PE, Yankaskas JR, and Bennett WD: Airway retention of materials of different solubility following local intrabronchial deposition in dogs. J Aerosol Med. 2003;16:153-166.
37. Alexis NE, Lay JC, Zeman KL, Geiser M, Kapp N, and Bennett WD: In vivo particle uptake by airway macrophages in healthy volunteer. Am J Respir Cell Mol Biol. 2006;34:305-313.
38. 99m-albumin colloid in the study of mucociliary clear¬ance. Dan Med Bull. 1998;45:195-209.
39. 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest. 1993;103:805-811.
40. Regnis JA, Zeman KL, Noone PG, Knowles MR, and Bennett WD: Prolonged airway retention of insoluble particles in cystic fibrosis vs. primary ciliary dyskinesia. Exp Lung Res. 2000;26:149-162.
41. Daviskas E, Anderson SD, Eberl S, Chan H-K, and Young IH: The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest. 2001; 119:414-421.
42. Ilowite J, Smaldone GC, Perry R, Bennett WD, and Foster WM: The relationship between tracheobronchial clearance rates and sites of initial deposition in man. Arch Environ Health. 1989;44:267-273.
43. Garrard CS, Gerrity TR, Schreiner JF, and Yeates DB: The characterization of radioaerosol deposition in the healthy lung by histogram analysis. Chest. 1981;80(Suppl):840-842.
44. Fleming JS, and Conway JH: Three-dimensional imaging of aerosol distribution. J Aerosol Med. 2001;14:147-153.
45. 2 agonists. Respir Med. 2005;99: 145-151.
46. Donaldson SH, Bennett WD, Zeman KL, Knowles MK, Tarran R, and Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-250.
47. Robinson M, Regnis JA, Bailey DL, King M, Bbautovich GJ and Bye PTP: Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fi-brosis. Am J Respir Crit Care Med. 1996;153:1503-1509.
48. Noone PG, Bennett WD, Regnis JA, Zeman KL, Carson JL, King M, Boucher RC, and Knowles MR: Effect of aerosolized uridine-5-triphoshate (UTP) on airway clearance with cough in patients with primary ciliary dyskinesia. Am J Resp Crit Care Med. 1999;160:144-149.
49. Sood N, Bennett WD, Zeman K, Brown J, Foy C, Boucher RC, and Knowles MR: Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Resp Crit Care Med. 2003;167:158-163.
50. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Geary CA, Boucher RC, and Knowles MR: Effect of uridine 5-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Resp Crit Care Med. 1996;153: 1796-1801.
51. Mortensen J, Groth S, Lange P, and Hermansen F: Effect of terbutaline on mucociliary clearance in asthmatic and heal¬thy subjects after inhalation from a pressurised inhaler and a dry powder inhaler. Thorax. 1991;46:817-823.
52. Smaldone GC, Foster WM, O'Riordan TG, Messina MS, Perry RJ, Langenback E: Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest. 1993;103:1390-1396.
53. Perring S, Summers Q, Fleming JS, Nassim MA, and Holgate ST: A new method of quantification of the pulmonary re¬gional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium adminis¬tered by metered dose inhaler. Br J Radiol. 1994;67:46-53.
54. Bennett WD, Zeman KL, Foy C, Shaffer C, Johnson F, Regnis J, Sannuti A, and Johnson J: Effect of aerosolized INS316 on mucociliary clearance in mild chronic bronchitis. Am J Resp Crit Care Med. 2001;164:302-306.
55. Goodman RM, Yergin BM, Landa JF, Golinvaux MH, and Sackner MA: Relationship of smoking history and pulmo¬nary function tests to tracheal mucous velocity in non-smokers, young smokers, ex-smokers, and patients with chronic bronchitis. Am Rev Respir Dis. 1978;117:205-214.
56. Robinson M, Eberl S, Tomlinson C, Daviskas E, Regnis JA, Bailey DL, Torzillo PJ, Menache M, and Bye PT: Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med. 2000;13:73-86.
57. Bateman JRM, D Pavia, NF Sheahan, JE Agnew, and Clarke SW: Impaired tracheobronchial clearance in patients with mild stable asthma. Thorax. 1983;38:463-467.
58. O'Riordan TG, Zwang J, and Smaldone GC: Mucociliary clearance in adult asthma. Am Rev Respir Dis. 1992;146: 598-603.
59. Messina MS, O'Riordan TG, and Smaldone GC: Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis. 1991;143:993-997.
60. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT, and the National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354: 229-240.
61. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertosn CF, Bye PTP, LeSouef P, Shadbolt B, Anderson SD, and Charlton B: Inhaled mannitol im¬proves lung function in cystic fibrosis. Chest. 2008;133: 1388-1396.
62. Daviskas E, Anderson SD, Jaques A, Charlton B: Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest. 2010;137: 861-868.